According to Fox News, the FDA’s latest MAHA (Maximum Allowable Human Amount) move would eliminate fluoride prescriptions for children, citing mounting health risk evidence (Fox News, May 13, 2025). This regulatory action could negatively impact pharmaceutical companies with fluoride-based pediatric products, potentially increasing volatility for related pharma stocks. In the crypto market, traders should monitor tokenized pharma equity assets and DeFi health sector tokens, as regulatory changes often lead to short-term price fluctuations driven by sentiment and sector rotation.